A combination therapy of lipid-lowering and an antiplatelet agent is widely used in the management of cardiovascular diseases. (Chen Ning, 2021) Manages elevated lipid levels and reduces the risk of cardiovascular events in patients with hyperlipidemia. (Chen Ning, 2021) Effectively treats hypercholesterolemia with an excellent effect of lowering blood lipids. (Hongyun Gao, 2022) Improves the lipid profile, enables patients to achieve lipid goals and slows the progression of atherosclerosis and improves cardiovascular outcomes. (Schuster, 2007) Lowers both total cholesterol and low-density lipoprotein cholesterol levels and increases high-density lipoprotein cholesterol levels. (Han, 2019) Ameliorates cardiac function and reduces the levels of blood lipids and inflammatory factors in elderly patients with coronary heart disease. (Hongyun Gao, 2022) Alleviates and blocks the progression of atherosclerosis and stabilizes atherosclerotic plaques. (Hongyun Gao, 2022) Lowers the risk of cardiovascular disease and coronary events like heart attack, stroke, and heart-related chest pain. Decreases secondary vascular events such as thromboembolism in patients with atherosclerosis. (Han, 2019) Possesses excellent inhibitory properties of platelet aggregation and reduces cardiovascular risks in patients with multiple co-morbid conditions such as stroke, myocardial infarction and atherosclerosis. (Ramesh Mullangi, 2009)

A ternary combination of blood-thinning and cholesterol-lowering drugs is used for atherosclerotic patients suffering from various heart diseases. (S. V. Londhe, 2011) A potent treatment of choice in acute coronary syndromes and prevention of thrombosis after coronary stent implementation. (A.M. SPIRIDON, 2015) Blocks the platelet adenosine diphosphate receptor, and powerfully inhibits platelet activation, degranulation, and aggregation. (Jehangir N Din, 2005) A therapeutic strategy that reduces cardiovascular risk, prevents ischemic stroke, myocardial infarction, and vascular disease. (S. V. Londhe, 2011) Reduces total cholesterol levels, low-density lipoprotein-cholesterol, triglyceride, and very low-density lipoprotein cholesterol and increases high-density lipoprotein-cholesterol. (H S Malhotra, 2001) Decreases the incidences of ischemic events and ameliorates survival in patients with acute coronary syndromes. (A.M. SPIRIDON, 2015) A potent drug that has the ability to reduce cardiovascular disease by stopping the growth of plaques in artery walls. (Ursula Gresser, 2004)

An antihypertensive agent to treat high blood pressure in patients whose blood pressure is not adequately controlled with monotherapy of cilnidipine/telmisartan/chlorthalidone or dual therapy. Relaxes blood vessels, reduces fluid retention, and lowers blood pressure effectively. Relaxes and widens blood vessels and improves the blood flow and oxygen supply to the heart. Promotes increased urine production and eliminates excess fluid from the body. Produces slightly greater reductions in blood pressure compared with hydrochlorothiazide. (Springer, 2015) Exhibits promising potential in decreasing the risk of cardiovascular events among high-risk patients. (Philippe R Akhrass, 2011) An effective strategy for the treatment of hypertension and related complications. (Jun-Hwan Jo, 2021) A favorable choice in hypertension therapy that manages high blood pressure and prevents cardiovascular events. (Albertus J Kooter, 2010) Significantly reduces systolic blood pressure, diastolic blood pressure, and pulse rate in hypertensive patients. (Rabindra Nath Chakraborty, 2021)

A lipid-lowering agent that is used in the treatment of high levels of fats. A highly effective drug in reducing low-density lipoprotein cholesterol, and increasing high-density lipoprotein cholesterol. (Anders G Olsson, 2002) More effective than other statins in reducing low-density lipoprotein, triglyceride, and total cholesterol levels. (Michael F Bullano, 2006) Improves cholesterol levels which prevent blockages from forming in arteries. Lessens the risk of cardiovascular events and stabilizes atherosclerosis. (Toth, 2014) A cost-effective statin option in treating low-density lipoprotein cholesterol goals in patients with hypercholesterolemia. (Mark Hirsch, 2005) A valuable addition to the statin drug class. (Cheng-Lai, 2003)

Women’s health support capsules that are purposefully manufactured with natural ingredients for managing uterine-related women's problems. Rejuvenates the female body and improves the functioning of the ovaries. A beneficial remedy that is highly effective in problems related to the female reproductive system. (Komal Sharma, 2011) An appropriate solution to conditions related to hormone imbalance such as polycystic ovarian syndrome and infertility. A rejuvenating herb that is beneficial in female infertility, cures inflammation of sexual organs and even moistens dry tissues of the sexual organs. (Komal Sharma, 2011) Combats female reproductive disorders like polycystic ovarian syndrome, irregular menstrual cycle, abnormally heavy or prolonged bleeding, and menstrual discomfort. Improves the functioning of the reproductive system and promotes a healthy sexual and reproductive balance. (Narendra Singh, 2011) A potential candidate that improves hormonal balance and regularises the period cycle. A potent medicinal plant that cures spasmodic pain and is effective for patients with menorrhagia and leucorrhea. Significantly reduces the severity of symptoms associated with primary dysmenorrhea. (Sima Younesy, 2014)

A combination drug of blood-thinning agents and cholesterol-lowering agents for atherosclerotic patients suffering from various heart diseases. (Mahmoud Mohamed Issa, 2013) Works by preventing platelets from forming clots that may cause a heart attack or stroke. Blocks the platelet adenosine diphosphate receptor, and powerfully inhibits platelet activation, degranulation, and aggregation. (Jehangir N Din, 2005) A powerful compound that has the ability to reduce cardiovascular disease by stopping the growth of plaques in artery walls. (Ursula Gresser, 2004) Demonstrates considerable success at reducing thrombotic complications of acute coronary syndrome and percutaneous coronary intervention. (Abu-Fadel, 2009) Significantly reduces total cholesterol, triglyceride, and low-density lipoprotein cholesterol in hypercholesterolemia patients. (Chumpol Piamsomboon 1, 2002) Prevents cardiovascular events in patients at higher risk of cardiovascular disease, as well as in those with acute coronary syndrome. (Christopher W. Walker, 2007) Exerts antiplatelet effects by inhibiting thromboxane A2 production and adenosine diphosphate-induced platelet aggregation pathways. (Hani Jneid, 2003) Reduces the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. (J Floris S Logman, 2010) Decreases levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride, and very low-density lipoprotein (VLDL)-cholesterol and increases high-density lipoprotein (HDL)-cholesterol in patients with a wide variety of dyslipidaemias. (H S Malhotra, 2001) Offers additional benefits for those patients at high risk and those with established cardiovascular disease. (T T Keller, 2007)

An anti-hypertensive agent that works synergistically to lowers blood pressure in mild to moderate or severe hypertensive patients. (Benedict, 2000) Provides a promising approach to the treatment of hypertension. (I Tikkanen, 1995) A well-tolerable drug that produces greater reduction in systolic and diastolic blood pressure. (J H MacKay, 1996) An excellent choice as antihypertensive therapy for patients in whom combination therapy is necessary to achieve additional blood pressure reduction. (Masanori Abe, 2009) More efficacious in lowering diastolic blood pressure (DBP) and systolic blood pressure (SBP) than monotherapy in hypertensive patients. (Takao Saruta, 2007) A well tolerated agent in mild, moderate, and severe essential hypertension. (Burrell, 1997) A favorable therapeutic option for obese patients with poorly controlled hypertension. (Chikao Ibuki, 2014)